Peptides for Hormonal Symptom Control
Comprehensive guide to 2 peptides researched for hormonal symptom control, ranked by evidence strength from FDA-approved to early preclinical. Each compound is evaluated on mechanism, clinical status, and safety profile.
Overview
2 research peptides are currently studied for hormonal symptom control. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Octreotide — FDA Approved
Evidence Rating: A
Category: Endocrine / Somatostatin Analog
Octreotide is a synthetic 8-amino-acid cyclic peptide (MW ~1019.2 g/mol) that mimics the pharmacological actions of natural somatostatin but with a significantly longer half-life. It was the first somatostatin analog approved by the FDA (1988) and is available as both an immediate-release subcutaneo...
Key claims: Controls symptoms and biochemical markers in acromegaly; Controls carcinoid syndrome symptoms.
Lanreotide — FDA Approved
Evidence Rating: A
Category: Endocrine / Somatostatin Analog
Lanreotide is a synthetic 8-amino-acid cyclic somatostatin analog (MW ~1096.3 g/mol) available as a long-acting deep subcutaneous depot injection (Somatuline Depot/Autogel). It is FDA-approved for acromegaly and for the treatment of unresectable, well- or moderately-differentiated, locally advanced ...
Key claims: Controls GH and IGF-1 in acromegaly; Extends progression-free survival in GEP-NETs.
Shop Research Peptides
Retatrutide 20mg
20mg
BPC-157 5mg
5mg
Ipamorelin 10mg
10mg
Semaglutide 10mg
10mg
TB-500 5mg
5mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Sermorelin 5mg
5mg
Tesamorelin 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe